Osteoporosis drug development welcomed

8 March 2016

Biopharmaceutical research companies in the USA are working to advance the treatment of osteoporosis with nine medicines in development, according to a new report.

The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Osteoporosis Foundation (NOF) welcomed the news in their joint report, Medicines in Development for Osteoporosis.

Nearly 54 million Americans live with osteoporosis or low bone density, and that number is expected to reach more than 71 million by 2030. Half of women and a quarter of men over the age of 50 are expected to break a bone as a result of osteoporosis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK